<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04121507</url>
  </required_header>
  <id_info>
    <org_study_id>ASTRAL / GLA-aNHL-R1</org_study_id>
    <nct_id>NCT04121507</nct_id>
  </id_info>
  <brief_title>ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy</brief_title>
  <official_title>A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective Phase II clinical study to assess the efficacy and toxicity of high dose&#xD;
      chemotherapy (HDT) followed by allogeneic stem cell transplantation (allo- or autoSCT) as&#xD;
      treatment of primary progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL) - ASTRAL&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a clinical study to assess the treatment (efficacy and toxicity) with a high dosed&#xD;
      chemotherapy followed by stem cell transplantation in patients suffering from primary&#xD;
      progressive and relapsed aggressive Non-Hodgkin Lymphoma (NHL)&#xD;
&#xD;
      After end of the active study phase, patients will receive further standard medical care at&#xD;
      the discretion of the treating physician. The clinical consultants will provide advice on&#xD;
      further treatment if requested.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of efficacy variables, Rate of Progression free survival (PFS)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>To compare a defined high dose therapy (HDT) with study medication followed by alloSCT lead to treatment results in terms of PFS, that are better than results obtained with high-dose therapy and autoSCT in a comparable Patient Population ( historical data).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of complete remissions (CR)</measure>
    <time_frame>1 year after stem cell transplantation (SCT)</time_frame>
    <description>Number of complete remissions divided by the number of patients (CR),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of partial remissions (PR)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>Number of partial remissions divided by the number of patients (PR);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of complete and partial remissions (ORR)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>Number of complete and partial remissions divided by the number of patients (ORR);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of progressive diseases (PD)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>Number of progressive diseases after SCT divided by the number of patients (PD);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of relapse (RR)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of treatment-related mortality</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>treatment-related death divided by the number of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of event free survival at 1 year (EFS)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of overall survival at 1 year (OS)</measure>
    <time_frame>1 year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of non-relapse mortality (NRM)</measure>
    <time_frame>1year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Causes of death</measure>
    <time_frame>1year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Incidence and severity of acute and chronic graft versus host disease (GvHD);</measure>
    <time_frame>until the last Follow-Up Visit ( 1-2 Year after SCT)</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Adverse events (AEs) grade 3 and 4</measure>
    <time_frame>until about day 100 after SCT.</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Serious adverse events (SAEs)</measure>
    <time_frame>until about day 100 after SCT.</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of number of blood cells</measure>
    <time_frame>1year after SCT</time_frame>
    <description>recovery of White blood cells and platelets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of efficacy variables, Rate of infections</measure>
    <time_frame>1year after SCT</time_frame>
    <description>safety item</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Aggressive Non-hodgkin Lymphoma (aNHL)</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, T-Cell</condition>
  <arm_group>
    <arm_group_label>alloSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>defined high-dose chemotherapy (HDT) followed by allogeneic stem cell transplantation (alloSCT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)</intervention_name>
    <description>High-dose therapy (HDT) prior to alloSCT will consist of FTC</description>
    <arm_group_label>alloSCT</arm_group_label>
    <other_name>fludarabine, thiotepa ,cyclophosphamide (FTC)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow histology</intervention_name>
    <description>Bone marrow histology at staging and restaging is only mandatory if the bone marrow was initially involved</description>
    <arm_group_label>alloSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>clinical and laboratory parameters</intervention_name>
    <description>During staging and restaging examinations, all clinical and laboratory parameters relevant for therapy.</description>
    <arm_group_label>alloSCT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PET-CT or CT</intervention_name>
    <description>Metabolic CR in a PET-CT scan after the last cycle of therapy prior to planned SCT. Consists preferably of a PET-CT or a CT scan according to local practice and other appropriate diagnostic procedures with respect to the sites of primary involvement.</description>
    <arm_group_label>alloSCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must fulfill all of the following criteria to be included in this trial:&#xD;
&#xD;
          1. Provision of written informed consent and specifically the consent to the collection&#xD;
             and processing of health-related data&#xD;
&#xD;
          2. Age: 18 years and older&#xD;
&#xD;
          3. Gender: Male and female patients&#xD;
&#xD;
          4. Histology&#xD;
&#xD;
          5. Diagnosis of relapsed or primary progressive aggressive B- or T-cell lymphoma&#xD;
             including:&#xD;
&#xD;
               1. B-Cell non-hodgkin lymphoma (B-NHL) or&#xD;
&#xD;
               2. T-Cell non-hodgkin lymphoma (T-NHL):&#xD;
&#xD;
          6. Staging at relapse or progression (data should not be older than 4 weeks):&#xD;
&#xD;
          7. Staging after 2 or 3 cycles of salvage treatment:&#xD;
&#xD;
          8. Donor availability:&#xD;
&#xD;
          9. Females of childbearing potential (FCBP) must:&#xD;
&#xD;
               -  Understand the potential teratogenic risk to the unborn child&#xD;
&#xD;
               -  Understand the need and agree to utilize two reliable forms of contraception&#xD;
&#xD;
               -  Understand and agree to inform the investigator if a change or stop of method of&#xD;
                  contraception is needed&#xD;
&#xD;
               -  Be capable of complying with effective contraceptive measures&#xD;
&#xD;
               -  Be informed and understand the potential consequences of pregnancy and the need&#xD;
                  to notify her study doctor immediately if there is a risk of pregnancy&#xD;
&#xD;
               -  Understand the need to commence the study treatment as soon as study drug is&#xD;
                  dispensed following a negative pregnancy test&#xD;
&#xD;
               -  Understand the need and accept to undergo pregnancy testing based on the&#xD;
                  frequency outlined in this protocol&#xD;
&#xD;
               -  Agree to abstain from breastfeeding during study participation&#xD;
&#xD;
         10. Males must:&#xD;
&#xD;
               -  Agree to use a latex condom during any sexual contact with females of&#xD;
                  childbearing potential&#xD;
&#xD;
               -  Agree to refrain from donating semen or sperm while on the study drugs and should&#xD;
                  seek for sperm cryopreservation before therapy is started and should not father a&#xD;
                  child while treated and during one year after end of study treatment&#xD;
&#xD;
         11. Females of non-childbearing potential:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are to be excluded from the study if they display any of the following criteria:&#xD;
&#xD;
          1. Pregnant females; lactating women must end breast feeding before start of study&#xD;
             treatment&#xD;
&#xD;
          2. Serious accompanying disorder or impaired organ function&#xD;
&#xD;
          3. Central nervous system (CNS) involvement of lymphoma - to be examined in case of&#xD;
             clinical symptoms&#xD;
&#xD;
          4. History of severe cardiac diseases, and cardiac function impairment&#xD;
&#xD;
          5. Severe kidney disease&#xD;
&#xD;
          6. HIV-positivity&#xD;
&#xD;
          7. Hepatitis B and C as defined by seropositivity&#xD;
&#xD;
          8. Patients under legal guardianship regarding medical decisions&#xD;
&#xD;
          9. Ongoing treatment or study procedures within any other clinical trial with the&#xD;
             exception of follow up&#xD;
&#xD;
         10. Ongoing exclusion periods of other clinical studies after end of treatment&#xD;
&#xD;
         11. In patients tested: Metabolic Computer tomography (CR) in a positron emission&#xD;
             tomography-Computer tomography (PET-CT) scan after the last cycle of therapy prior to&#xD;
             planned SCT&#xD;
&#xD;
         12. Subjects with known hypersensitivity to the study drugs&#xD;
&#xD;
         13. Criteria which in the opinion of the investigator precluded participation for&#xD;
             scientific reasons, for reasons of compliance, or for reasons of the subject's safety&#xD;
&#xD;
         14. Commitment to an institution by virtue of an order issued either by the judicial or&#xD;
             the administrative authorities&#xD;
&#xD;
         15. Dependency on the sponsor, trial site or investigator&#xD;
&#xD;
         16. Additional exclusion criteria with respect to summary of product characteristics&#xD;
             (SmPC) of the investigational medical product (IMPs) fludarabine, thiotepa,&#xD;
             cyclophosphamide:&#xD;
&#xD;
               1. Known hypersensitivity to fludarabine, thiotepa, cyclophosphamide or one of their&#xD;
                  metabolites&#xD;
&#xD;
               2. Renal impairment&#xD;
&#xD;
               3. Decompensated haemolytic anaemia&#xD;
&#xD;
               4. Concurrent application of vital vaccines&#xD;
&#xD;
               5. Cystitis&#xD;
&#xD;
               6. Renal tract obstruction&#xD;
&#xD;
               7. Active and uncontrolled infection&#xD;
&#xD;
               8. Notice: myelosuppression and impaired hematopoietic function is not an exclusion&#xD;
                  criterion as this usual contraindication to the application to any of the IMPs&#xD;
                  will be overcome by the stem cell transplantation following conditioning therapy.&#xD;
&#xD;
                  -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertram Glass, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinikum Berlin-Buch</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katrin Linke, Dr.</last_name>
    <phone>: +49 (0) 351 25933 176</phone>
    <email>Katrin.linke@gwtonline.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carsta Köhler, Dr.</last_name>
    <phone>+ +49 (0) 351 25933 190</phone>
    <email>'bertram.glass@helios-gesundheit.de'</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HELIOS Klinik Berlin-Buch, Klinik für Hämatologie und Stammzelltransplantation</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertram Glaß, Prof. Dr.</last_name>
      <phone>+ 49 (0) 30 940 11 21 02</phone>
      <email>'bertram.glass@helios-gesundheit.de'</email>
    </contact>
    <investigator>
      <last_name>Bertram Glaß</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, Medizinische Klinik II</name>
      <address>
        <city>Augsburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Schmid, Dr.</last_name>
      <phone>+ 49 (0) 821 / 400 37 15</phone>
      <email>christoph.schmid@klinikum-augsburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Dr.</last_name>
    </contact_backup>
    <investigator>
      <last_name>Christoph Schmid, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Universitätsklinikum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schroers</last_name>
      <email>roland.schroers@rub.de</email>
    </contact>
    <investigator>
      <last_name>Roland Schroers, Prof.Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, Dr.</last_name>
      <email>m.haenel@skc.de</email>
    </contact>
    <investigator>
      <last_name>Mathias Hänel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden, Medzinische Klinik I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Friedrich Stölzel, Dr.</last_name>
      <phone>+ 49 (0) 351 45 8 25 83</phone>
    </contact>
    <investigator>
      <last_name>Friedrich Stölzel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäsklinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Kobbe, Prof.Dr.</last_name>
      <email>Kobbe@med.uni-duesseldorf.de</email>
    </contact>
    <investigator>
      <last_name>Guido Kobbe, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen Klinik für Hämatologie/Med. Onkologie</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Justin Hasenkamp, Dr.</last_name>
      <phone>+49 (0) 5513914289</phone>
      <email>justin.hasenkamp@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Justin Hasenkamp, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lutz Müller, Dr.</last_name>
      <email>lutz.mueller@uk-halle.de</email>
    </contact>
    <investigator>
      <last_name>Lutz Müller, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf, Zentrum für Onkologie, Interdisziplinäre Klinik und Poliklinik für Stammzelltransplantation</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Wolschke, Dr.</last_name>
      <phone>+ 49 (0) 40 / 741 05 81 25</phone>
      <email>wolschke@uke.de</email>
    </contact>
    <investigator>
      <last_name>Christine Wolschke, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg, Medizinische Klinik, Innere Medizin V</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Dreger, Prof. Dr.</last_name>
      <phone>+49 (0) 6221 / 56 82 83</phone>
      <email>peter.dreger@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Peter Dreger, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Innere Medizin, Abtl. Hämatologie und Innternistische Onkologie</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inken Hilgendorf, Dr.</last_name>
      <phone>+49 (0)3641 / 932 46 64</phone>
    </contact>
    <investigator>
      <last_name>Inken Hilgendorf, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, KMT-Zentrum/ Med. Klinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <phone>+ 49 (0) 251 / 835 28 01</phone>
      <email>matthias.stelljes@ukmuenster.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Stelljes, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Illerhaus, Prof.Dr.</last_name>
      <email>g.illerhaus@klinikum-stuttgart.de</email>
    </contact>
    <investigator>
      <last_name>Gerald Illerhaus, Prof.Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 31, 2019</study_first_submitted>
  <study_first_submitted_qc>October 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

